Clinical Trial Update: Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients. [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 open-label trial evaluating the safety and efficacy of concomitant administration of anti-CD19 CAR T-cell therapy and Lenalidomide in relapsed/refra…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Anti-CD19 CAR-T cell therapy (CD19-targeted chimeric antigen receptor T cells)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Vitebsk Regional Clinical Cancer Centre | Conditions: Chronic Lymphocytic Leukaemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 1, Phase 2 | Status: ENROLLING_BY_INVITATION